Hair loss

Immusoft Administers the First Engineered B Cell in a Human Clinical Trial

Retrieved on: 
Friday, December 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Disease, Regenerative medicine, Research, IDUA, MPS I, MPS, Therapy, Immunosuppression, Risk, Clinical trial, CIRM, Patient, ISP, Sugar, Division, Pediatric Blood & Cancer, Heart, DSM-IV codes, Infertility, Nausea, Infection, University, Cell, Hair loss, Pharmaceutical industry, Vaccine

Neither chemotherapy nor immunosuppression is required by Immusoft’s novel engineered B cell approach.

Key Points: 
  • Neither chemotherapy nor immunosuppression is required by Immusoft’s novel engineered B cell approach.
  • Immusoft has pioneered B cell engineering to create biofactories for durable in vivo therapeutic protein delivery, leading the field with over 60 issued and pending patents.
  • “Immusoft is advancing the world’s first engineered B cell therapy, which may have significant impact for patients with this rare disease and potentially many others.
  • We are excited by the potential of expanding the Immusoft engineered B cell platform to trials in additional therapeutic areas,” said Robert Sikorski, M.D., Ph.D., Chief Medical Officer, Immusoft.

WANTIFO Launches Hair Dryer DualCare with Advanced Plasma Ionic Tech

Retrieved on: 
Saturday, December 9, 2023
Safety, Noetics, Noise, UL, ALCI, Hair loss, Temperature, Amazon, Travel

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- Wantifo , leading the beauty tech industry, introduces the WANTIFO Hair Dryer DualCare , now available on Amazon.US.

Key Points: 
  • NEW YORK, Dec. 8, 2023 /PRNewswire/ -- Wantifo , leading the beauty tech industry, introduces the WANTIFO Hair Dryer DualCare , now available on Amazon.US.
  • The WANTIFO Hair Dryer DualCare, boasting a high-speed 110,000 RPM brushless motor and cutting-edge Plasma Ionic Technology, emits 200 million positive and negative ions.
  • Efficient by design, the WANTIFO Hair Dryer DualCare ensures quick drying without heat damage.
  • For more information on the DualCare Hair Dryer, please contact:

LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada.

Retrieved on: 
Monday, December 4, 2023
NOC, Health Canada, Immune system, Patient, Alopecia areata, Autoimmune disease, Mental health, Quality of life, Pfizer, Hair loss, Scalp, Face, Vaccine, Nursing, QC, Dermatology

A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata.

Key Points: 
  • A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata.
  • KIRKLAND, QC, Dec. 4, 2023 /CNW/ - Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for LITFULO™ (ritlecitinib).
  • "Until now, there have been no approved medical treatment options to help patients and their families living with this condition.
  • The alopecia community across Canada is looking forward to access to a new treatment option for both adolescents and adults with the severe form of alopecia areata."

Veradermics Co-Founder and CEO, Reid Waldman, Named to the 2023 Forbes "30 Under 30" Healthcare List

Retrieved on: 
Wednesday, November 29, 2023
Entrepreneurship, Wart, Clinical trial, Medicine, American Academy, Cedars-Sinai Medical Center, University, Pattern hair loss, Atopic dermatitis, Therapy, American Academy of Dermatology, Health care, Health, Skin, Physician, Publication, Hair loss, Molluscum contagiosum, Pharmaceutical industry, Dermatology

NEW HAVEN, Conn., Nov. 29, 2023 /PRNewswire-PRWeb/ -- Veradermics Inc., a clinical-stage medical dermatology company developing new therapeutics for a range of skin and hair loss conditions, today announced that Co-Founder and CEO, Reid Waldman, has been included in the 2023 Forbes "30 Under 30" Healthcare list, recognizing leading scientists and entrepreneurs developing innovative solutions that address some of healthcare's biggest challenges.

Key Points: 
  • Two products of which Waldman is an inventor, including an immune stimulatory microarray for warts and a non-hormonal oral therapeutic for androgenetic alopecia, are currently in clinical trials.
  • In a significant milestone, the company recently announced the dosing of the first patient in a clinical trial for its non-hormonal oral therapeutic for pattern hair loss.
  • In addition to the two therapeutics currently in trials for warts and pattern hair loss, Veradermics pipeline also includes candidates targeting alopecia areata, atopic dermatitis, and molluscum contagiosum.
  • The company expects to advance these additional product candidates into the clinic in 2024.

Organic antibacterial preservative of ANDKWAN to protect both people and nature

Retrieved on: 
Thursday, November 23, 2023
Motivation, Carbon, Food, Multimedia, Nature, Staphylococcus aureus, Health, Cosmetics, Escherichia coli, Hair loss, Vaccine

According to Kwanyoung Park, CEO of AndKwan Natural Science Inc. the new material will be distributed worldwide under the trade name 'Immune Barrier CellTM'.

Key Points: 
  • According to Kwanyoung Park, CEO of AndKwan Natural Science Inc. the new material will be distributed worldwide under the trade name 'Immune Barrier CellTM'.
  • Immune Barrier Cell symbolizes the antibacterial and immune effects among the various effects of WTGPhLATM.
  • WTGPhLATM is an organic antibacterial preservative that has a highly effective antibacterial spectrum against pathogenic strains such as Staphylococcus aureus, pneumoniae, Escherichia coli, and black mold, and has passed preservative and antibacterial tests from the international KOLAS certified testing and analysis agency.
  • In other words, we want to create a world where people can feel safe through the organic antibacterial preservatives, WTGPhLATM for the health of both nature and people."

Dr. Ran Rubinstein Opens a New Cosmetic Surgery Office Serving Montvale, NJ

Retrieved on: 
Monday, November 20, 2023
PRP, Practitioner, Columbia, New York, Neurotoxin, Patient satisfaction, Anatomy, Surgeon, Patient, Multimedia, Faculty, Rejuvenation, Elective surgery, Teaching, Center of excellence, Filler (linguistics), Breast augmentation, Society, Rhinoplasty, Knowledge, Hair loss, Health, Hospital, Education, Dentistry, Nursing, Medical device, Sculptra

MONTVALE, N.J., Nov. 20, 2023 /PRNewswire-PRWeb/ -- Expanding Reach: New Montvale Office for Dr. Ran Rubinstein

Key Points: 
  • The new Rubinstein Plastic Surgery Center in Montvale, New Jersey, will allow Dr. Rubinstein to reach more patients.
  • Ran Rubinstein
    The opening of the new Rubinstein Plastic Surgery Center location is a significant milestone in Dr. Rubinstein's mission to make premium plastic surgery services accessible to more people.
  • Located at 160 Summit Ave Suite 201, Montvale, NJ 07645, the new office is conveniently accessible to patients in and around the area.
  • Training Future Plastic Surgeons in Montvale, NJ
    Dr. Rubinstein's commitment to the field of plastic surgery extends beyond his office doors.

Why a Dermatologist and Plastic Surgeon Who Run a Skin Cancer Center Researched and Developed An Edible SPF Booster

Retrieved on: 
Wednesday, November 15, 2023
Skin cancer, Research, Radiation, Amazon, Smash Mouth, Antioxidant, Collection, Polyphenol, Patient, UV, Weather, Rejuvenation, Nicotinamide, The Non-GMO Project, Polypodium, Swimming, Serenoa, Skin, Hair loss, Cosmetics, Withania somnifera, Collagen

Inner Glow has created Sol Defense ($29.99 at innerglowvitamins.com and amazon.com ), a delicious, passion fruit flavored gummy containing important ingredients that enhance sun protection.

Key Points: 
  • Inner Glow has created Sol Defense ($29.99 at innerglowvitamins.com and amazon.com ), a delicious, passion fruit flavored gummy containing important ingredients that enhance sun protection.
  • The second is Niacinamide which is known to help the body fight the development of precancers and skin cancers.
  • "This easy to take, on the go formula gives our patients an extra layer of sun protection," says Dr. Galaria.
  • Inner Glow Vitamins are the culmination of extensive research, development by a dermatologist and plastic surgeon with over 40 years of combined experience.

EBLUXE HAIR® ADDRESSES MISCONCEPTIONS CONCERNING HAIR EXTENSIONS AND NATURAL HAIR DAMAGE

Retrieved on: 
Friday, November 10, 2023
Woman, Way, Traction, Hair loss, Cosmetics

However, there has been a growing concern among some women about whether hair extensions cause damage to their natural hair.

Key Points: 
  • However, there has been a growing concern among some women about whether hair extensions cause damage to their natural hair.
  • This prompted EBLUXE HAIR® , a leading hair extension company, to address these concerns by providing insight about the potential effects of hair extensions on natural hair.
  • EBLUXE HAIR® also noted that when hair extensions are not properly installed or maintained it can lead to hair damage.
  • To ensure that customers are informed and knowledgeable about how to properly wear hair extensions, EBLUXE HAIR® provides a comprehensive guide on their website, covering Ways to avoid damage to your natural hair while wearing hair extensions .

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Retrieved on: 
Wednesday, November 8, 2023
Stroke, FDA, Eli Lilly and Company, Research, Physiology, Lilly, Constipation, Abdominal pain, Excipient, Insurance, United Kingdom, NYSE, Food, Hair loss, Health, BMI, Obesity, Government, Vomiting, GIP, Hope, Weight loss, Diarrhea, Blood pressure, LLY, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diabetes, Tirzepatide, Cholesterol, News, Esophagitis, Exercise, Gastroparesis, Nausea, Pancreatitis, Type, Conditional sentence, Burping, Disease, Clinical trial, Thyroid cancer, Hypertension, Medication, Pharmacy, Diet, Indigestion, Overweight, Hunger, Gastrointestinal disease, Patient, Dyslipidemia, Obstructive sleep apnea, Hypersensitivity, Human, Cardiovascular disease, Fatigue, Pharmaceutical industry, Copper, Dietary supplement, Health insurance, Telescopic sight

INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.

Key Points: 
  • "Obesity is a chronic disease that can result in serious health complications, including heart disease, stroke and diabetes.
  • Despite our knowledge of obesity as a treatable, chronic disease, people living with obesity still face many challenges in their health and weight management journey," said Joe Nadglowski, president and chief executive officer of the Obesity Action Coalition.
  • "New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management."
  • Tirzepatide is also under regulatory review for weight management in Europe, China, the United Kingdom and several additional markets.

Rootique DUO launches on Indiegogo, revolutionizing hair loss treatment with a 15s mess-free process

Retrieved on: 
Tuesday, November 7, 2023
LED, Absorption, Minoxidil, MSRP, Patient, DUO, Hair, Hair loss, Massage, Scalp, Cosmetics, Indiegogo

For people experiencing hair loss, topical treatments like minoxidil have become a common choice to address their issues as it is clinically proven to work.

Key Points: 
  • For people experiencing hair loss, topical treatments like minoxidil have become a common choice to address their issues as it is clinically proven to work.
  • Rootique saw an opportunity to change the game and created Rootique DUO, the world's first micro-misting hair loss treatment device.
  • Rootique believes in providing a more enjoyable and efficient experience for individuals dealing with hair loss, and its product Rootique DUO aims to empower users to regain control over their hair health.
  • Rootique DUO is available for pre-order today starting at just $89 (MSRP: $149) through Indiegogo , with delivery starting in January 2024.